Study the role of Urotensin II as a predictor for hepatorenal syn | 52959
Journal of Clinical and Cellular Immunology

Journal of Clinical and Cellular Immunology
Open Access

ISSN: 2155-9899

+44 1223 790975

Study the role of Urotensin II as a predictor for hepatorenal syndrome

4th International Conference and Exhibition on Immunology

September 28-30, 2015 Crowne Plaza Houston River Oaks, Houston, TX, USA

Reda M EL-Badawy

Banha University, Egypt

Posters-Accepted Abstracts: J Clin Cell Immunol

Abstract :

Hepatorenal syndrome (HRS type 1, 2) is one of the serious complications of chronic liver disease with high mortality. The Aim: Of this study was to evaluate the diagnostic role of urotensin II in patients with chronic liver diseases ( both ascitic and non ascitic patients). Forty patients were selected, Group (1) 20 patients with ascites (9 males and 11 females). Group (2) 20 patients without ascites (8 males and 12 females) their age and sex matched. Results: For ALT, T.B, DB serum urea and platelet count, there was a statistically significant decrease between the 2 groups ( p<0.05). The Ultrasound findings of the kidney��?s were of statistically significant difference between the two groups as regard nephropathy (8 patients in ascitic group [1] while one patient in non ascitic group [2]) (p value <0.05). There was a statistically significant correlation between Urotensin II and blood urea level in group 2, . The cut-off value of Urotensin II was of sensitivity 66.7%, specificity 64.5%, PPV 35.3% and NPP 86.96% with Accuracy 59% and p value <0.42 of no statistically significant difference. Conclusion: Urotensin II was of statistically significant positive correlation with blood urea level in patients without ascites, that means the relevant clinical importance to use urotensin II in the early stages of liver disease, that is of crucial prognostic important for follow up.

Biography :